Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that CEO Graham Lumsden has been invited to present at BIO 2016 which is being held at the Moscone Center, 747 Howard Street, San Francisco from June 6-9 2016.
The presentation will provide information on the progress of its clinical lead antibiotic, iclaprim, into pivotal phase III trials and will be held in presentation room 1 on Monday June 6 commencing at 2.45pm.
The BIO convention brings together over 15,000 biotechnology and pharma leaders, covering a wide spectrum of life sciences areas including drug discovery, bio-manufacturing, genomics and more.
For further information please contact:
Motif Bio plc
Graham Lumsden (Chief Executive Officer)
info@motifbio.com
Walbrook PR Ltd
Paul McManus
Mike Wort
+44 (0)20 7933 8780 or motifbio@walbrookpr.com
Mob: +44 (0)7980 541 893
Mob: +44 (0)7900 608 002
Notes to Editors:
Motif Bio is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria. For additional information about Motif Bio please visit www.motifbio.com.
